Rallybio (NASDAQ: RLYB) director granted options in lieu of cash

Rhea-AI Filing Summary

Rallybio Corp director Ronald Hunt received an option grant to acquire 14,305 shares of common stock at $3.60 per share. The option was issued under the 2021 Equity Incentive Plan in lieu of $51,500 in retainer fees and vests in 11 equal monthly installments over the remaining months of 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUNT RONALD

(Last) (First) (Middle)

C/O RALLYBIO CORPORATION

234 CHURCH STREET

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rallybio Corp [ RLYB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to Buy)	$4.45	02/18/2026		A		14,305		(1)	02/18/2036	Common Stock	14,305	$3.6(2)	14,305	D

Explanation of Responses:

1. The option vests as to the underlying shares of Common Stock in 11 equal installments, each on the last day of each remaining month of calendar year 2026.

2. This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.

Remarks:

	By:/s/ Stephen Uden, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rallybio (RLYB) director Ronald Hunt report?

Ronald Hunt reported receiving an option grant to acquire 14,305 Rallybio shares at $3.60 per share. The award is compensation under the 2021 Equity Incentive Plan, structured as stock options instead of a cash retainer for his board service.

How many Rallybio (RLYB) shares are covered by Ronald Hunt’s option grant?

The option grant covers 14,305 underlying shares of Rallybio common stock. These options give Hunt the right to buy that number of shares at a fixed $3.60 exercise price, subject to the vesting schedule set for the remainder of calendar year 2026.

What is the exercise price of Ronald Hunt’s Rallybio (RLYB) stock options?

The stock options granted to Ronald Hunt have an exercise price of $3.60 per share. This means he can purchase Rallybio common shares at $3.60 once the options vest, according to the monthly vesting schedule during the remaining months of 2026.

How do Ronald Hunt’s Rallybio (RLYB) options vest over time?

The options vest in 11 equal installments, each on the last day of the remaining months in 2026. This creates a monthly vesting pattern, so portions of the 14,305 underlying shares become exercisable steadily throughout the rest of calendar year 2026.

Why did Rallybio (RLYB) grant options to Ronald Hunt instead of cash?

Rallybio issued this option grant to Ronald Hunt in lieu of $51,500 in retainer fees. Instead of paying that board compensation in cash, the company delivered equivalent value through options under its 2021 Equity Incentive Plan tied to Rallybio common stock.

Under which plan were Ronald Hunt’s Rallybio (RLYB) options granted?

The options were granted pursuant to Rallybio’s 2021 Equity Incentive Plan. This plan allows the company to compensate directors and other participants with equity-based awards, such as stock options, aligning their compensation with Rallybio’s share performance over time.